A fundamental philosophy of
medical oncology, including combination chemotherapy, is that different drugs work through different mechanisms, and that the results of using multiple drugs will be
synergistic to some extent. Because they have different dose-limiting
adverse effects, they can be given together at full doses in chemotherapy regimens.[1]
The first successful combination chemotherapy was
MOPP, introduced in 1963 for
lymphomas.
The term "
induction regimen" refers to a chemotherapy regimen used for the initial treatment of a disease. A "
maintenance regimen" refers to the ongoing use of chemotherapy to reduce the chances of a cancer
recurring or to
prevent an existing cancer from continuing to grow.[2]
Nomenclature
Chemotherapy regimens are often identified by
acronyms, identifying the agents used in the drug combination. However, the letters used are not consistent across regimens, and in some cases - for example, "BEACOPP" - the same letter combination is used to represent two different treatments.[3]
There is no widely accepted naming convention or standard for the nomenclature of chemotherapy regimens. For example, either
generic or
brand names may be used for acronyms. This page merely lists commonly used conventions.
^Mayer RJ (February 2009). "Targeted therapy for advanced colorectal cancer—more is not always better". N Engl J Med. 360 (6): 623–5.
doi:
10.1056/NEJMe0809343.
PMID19196680. letter commenting on the Clinical trial: Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, van Groeningen CJ, Sinnige HA, Richel DJ, Voest EE, Dijkstra JR, Vink-Börger ME, Antonini NF, Mol L, van Krieken JH, Dalesio O, Punt CJ (February 2009). "Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer". N Engl J Med. 360 (6): 563–72.
doi:
10.1056/NEJMoa0808268.
hdl:2066/79995.
PMID19196673.
^Kiesewetter B, Mayerhoefer ME, Lukas J, Zielinski CC, Müllauer L, Raderer M (2014). "Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma)". Ann. Hematol. 93 (2): 249–53.
doi:
10.1007/s00277-013-1865-3.
PMID23925930.
S2CID12851937.
^El Weshi, A; Memon, M; Raja, M; Bazarbashi, S; Rahal, M; El Foudeh, M; Pai, C; Allam, A; El Hassan, I; Ezzat, A (October 2004). "VIP (etoposide, ifosfamide, cisplatin) in adult patients with recurrent or refractory Ewing sarcoma family of tumors". American Journal of Clinical Oncology. 27 (5): 529–34.
doi:
10.1097/01.coc.0000135815.94162.83.
PMID15596925.
S2CID6362786.
A fundamental philosophy of
medical oncology, including combination chemotherapy, is that different drugs work through different mechanisms, and that the results of using multiple drugs will be
synergistic to some extent. Because they have different dose-limiting
adverse effects, they can be given together at full doses in chemotherapy regimens.[1]
The first successful combination chemotherapy was
MOPP, introduced in 1963 for
lymphomas.
The term "
induction regimen" refers to a chemotherapy regimen used for the initial treatment of a disease. A "
maintenance regimen" refers to the ongoing use of chemotherapy to reduce the chances of a cancer
recurring or to
prevent an existing cancer from continuing to grow.[2]
Nomenclature
Chemotherapy regimens are often identified by
acronyms, identifying the agents used in the drug combination. However, the letters used are not consistent across regimens, and in some cases - for example, "BEACOPP" - the same letter combination is used to represent two different treatments.[3]
There is no widely accepted naming convention or standard for the nomenclature of chemotherapy regimens. For example, either
generic or
brand names may be used for acronyms. This page merely lists commonly used conventions.
^Mayer RJ (February 2009). "Targeted therapy for advanced colorectal cancer—more is not always better". N Engl J Med. 360 (6): 623–5.
doi:
10.1056/NEJMe0809343.
PMID19196680. letter commenting on the Clinical trial: Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, van Groeningen CJ, Sinnige HA, Richel DJ, Voest EE, Dijkstra JR, Vink-Börger ME, Antonini NF, Mol L, van Krieken JH, Dalesio O, Punt CJ (February 2009). "Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer". N Engl J Med. 360 (6): 563–72.
doi:
10.1056/NEJMoa0808268.
hdl:2066/79995.
PMID19196673.
^Kiesewetter B, Mayerhoefer ME, Lukas J, Zielinski CC, Müllauer L, Raderer M (2014). "Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma)". Ann. Hematol. 93 (2): 249–53.
doi:
10.1007/s00277-013-1865-3.
PMID23925930.
S2CID12851937.
^El Weshi, A; Memon, M; Raja, M; Bazarbashi, S; Rahal, M; El Foudeh, M; Pai, C; Allam, A; El Hassan, I; Ezzat, A (October 2004). "VIP (etoposide, ifosfamide, cisplatin) in adult patients with recurrent or refractory Ewing sarcoma family of tumors". American Journal of Clinical Oncology. 27 (5): 529–34.
doi:
10.1097/01.coc.0000135815.94162.83.
PMID15596925.
S2CID6362786.